Get started
Author

Haris Jahić

Observed names: H. Jahic, Haris Jahic, Haris Jahic (20983013)
ORCID: 0009-0005-3755-8889
Observed ORCID: 0009-0005-3755-8889
OpenAlex ID: A5110044367
Avibactam is a covalent, reversible, non–β-lactam β-lactamase inhibitor
2012 · David E. Ehmann, Haris Jahić, et al. · Proceedings of the National Academy of Sciences · 572
PDF
Kinetics of Avibactam Inhibition against Class A, C, and D β-Lactamases
2013 · David E. Ehmann, Haris Jahić, et al. · Journal of Biological Chemistry · 384
Molecular Basis of Selective Inhibition and Slow Reversibility of Avibactam against Class D Carbapenemases: A Structure-Guided Study of OXA-24 and OXA-48
2014 · Sushmita D. Lahiri, Stefano Mangani, et al. · ACS Chemical Biology · 109
Discovery of TNG908: A Selective, Brain Penetrant, MTA-Cooperative PRMT5 Inhibitor That Is Synthetically Lethal with MTAP -Deleted Cancers
2024 · Kevin M. Cottrell, Kimberly J. Briggs, et al. · Journal of Medicinal Chemistry · 89
Reversibility of Covalent, Broad-Spectrum Serine β-Lactamase Inhibition by the Diazabicyclooctenone ETX2514
2017 · Adam B. Shapiro, Ning Gao, et al. · ACS Infectious Diseases · 68
Small molecule inhibitors and CRISPR/Cas9 mutagenesis demonstrate that SMYD2 and SMYD3 activity are dispensable for autonomous cancer cell proliferation
2018 · Michael J. Thomenius, Jennifer Totman, et al. · PLoS ONE · 62
PDF
SAR and Structural Analysis of Siderophore-Conjugated Monocarbam Inhibitors of Pseudomonas aeruginosa PBP3
2015 · Kerry E. Murphy-Benenato, Brian Dangel, et al. · ACS Medicinal Chemistry Letters · 30
A Homogeneous, High-Throughput Fluorescence Anisotropy-Based DNA Supercoiling Assay
2010 · Adam Shapiro, Haris Jahic, et al. · SLAS DISCOVERY · 30
PDF
Discovery of Efficacious Pseudomonas aeruginosa -Targeted Siderophore-Conjugated Monocarbams by Application of a Semi-mechanistic Pharmacokinetic/Pharmacodynamic Model
2015 · Kerry E. Murphy-Benenato, Pratik R. Bhagunde, et al. · Journal of Medicinal Chemistry · 29
A High-Throughput, Homogeneous, Fluorescence Resonance Energy Transfer-Based Assay for Phospho-N-acetylmuramoyl-pentapeptide Translocase (MraY)
2012 · Adam B. Shapiro, Haris Jahić, et al. · SLAS DISCOVERY · 26
MTA-Cooperative PRMT5 Inhibitors: Mechanism Switching Through Structure-Based Design
2025 · Kevin M. Cottrell, Douglas A. Whittington, et al. · Journal of Medicinal Chemistry · 16
PDF
Development of an LC–MS based enzyme activity assay for MurC: application to evaluation of inhibitors and kinetic analysis
2004 · Gejing Deng, Rong-Fang Gu, et al. · Journal of Pharmaceutical and Biomedical Analysis · 14
Identification through structure-based methods of a bacterial NAD+-dependent DNA ligase inhibitor that avoids known resistance mutations
2013 · Kerry Murphy-Benenato, Hongming Wang, et al. · Bioorganic & Medicinal Chemistry Letters · 12
From fragments to leads: novel bacterial NAD + -dependent DNA ligase inhibitors
2014 · Michael R. Hale, Claire Brassington, et al. · Tetrahedron Letters · 9
A Homogeneous, High-Throughput-Compatible, Fluorescence Intensity–Based Assay for UDP-N-Acetylenolpyruvylglucosamine Reductase (MurB) with Nanomolar Product Detection
2011 · Adam B. Shapiro, Stephania Livchak, et al. · SLAS DISCOVERY · 8
The kinetic mechanism of S. pneumoniae DNA ligase and inhibition by adenosine-based antibacterial compounds
2012 · Haris Jahić, Ce Feng Liu, et al. · Biochemical Pharmacology · 7
LIG1 Is a Synthetic Lethal Target in BRCA1 Mutant Cancers
2025 · Lauren Catherine M. Martires, Leanne G. Ahronian, et al. · Molecular Cancer Therapeutics · 6
PDF
Supplementary Figure S2 from LIG1 Is a Synthetic Lethal Target in BRCA1 Mutant Cancers
2026 · Lauren Catherine M. Martires, Leanne G. Ahronian, et al.
Supplementary Figure S6 from LIG1 Is a Synthetic Lethal Target in BRCA1 Mutant Cancers
2026 · Lauren Catherine M. Martires, Leanne G. Ahronian, et al.
Supplementary Figure S4 from LIG1 Is a Synthetic Lethal Target in BRCA1 Mutant Cancers
2026 · Lauren Catherine M. Martires, Leanne G. Ahronian, et al.
Supplementary Figure S7 from LIG1 Is a Synthetic Lethal Target in BRCA1 Mutant Cancers
2026 · Lauren Catherine M. Martires, Leanne G. Ahronian, et al.
Supplementary Figure S1 from LIG1 Is a Synthetic Lethal Target in BRCA1 Mutant Cancers
2026 · Lauren Catherine M. Martires, Leanne G. Ahronian, et al.
Supplementary Figure S3 from LIG1 Is a Synthetic Lethal Target in BRCA1 Mutant Cancers
2026 · Lauren Catherine M. Martires, Leanne G. Ahronian, et al.
Supplementary Figure S5 from LIG1 Is a Synthetic Lethal Target in BRCA1 Mutant Cancers
2026 · Lauren Catherine M. Martires, Leanne G. Ahronian, et al.
Supplementary Figure S6 from LIG1 Is a Synthetic Lethal Target in BRCA1 Mutant Cancers
2025 · Lauren Catherine M. Martires, Leanne G. Ahronian, et al.
Works count: 39
Citation count: 1,471
H-index: 12
I10-index: 13
Year
Topic
Type